HRP20160764T1 - Pseudovirusi papilomavirusa za otkrivanje i liječenje tumora - Google Patents
Pseudovirusi papilomavirusa za otkrivanje i liječenje tumoraInfo
- Publication number
- HRP20160764T1 HRP20160764T1 HRP20160764TT HRP20160764T HRP20160764T1 HR P20160764 T1 HRP20160764 T1 HR P20160764T1 HR P20160764T T HRP20160764T T HR P20160764TT HR P20160764 T HRP20160764 T HR P20160764T HR P20160764 T1 HRP20160764 T1 HR P20160764T1
- Authority
- HR
- Croatia
- Prior art keywords
- pseudoviruses
- papillomavirus
- tumors
- therapy
- detection
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 241001631646 Papillomaviridae Species 0.000 title 1
- 241001112090 Pseudovirus Species 0.000 title 1
- 238000001514 detection method Methods 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0097—Cells, viruses, ghosts, red blood cells, viral vectors, used for imaging or diagnosis in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
- A61K49/0476—Particles, beads, capsules, spheres
- A61K49/0485—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1203—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules in a form not provided for by groups A61K51/1206 - A61K51/1296, e.g. cells, cell fragments, viruses, virus capsides, ghosts, red blood cells, viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Optics & Photonics (AREA)
- Dispersion Chemistry (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92849507P | 2007-05-08 | 2007-05-08 | |
US6589708P | 2008-02-14 | 2008-02-14 | |
PCT/US2008/062296 WO2008140961A2 (en) | 2007-05-08 | 2008-05-01 | Papillomavirus pseudoviruses for detection and therapy of tumors |
EP08747407.8A EP2145189B1 (en) | 2007-05-08 | 2008-05-01 | Papillomavirus pseudoviruses for detection and therapy of tumors |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20160764T1 true HRP20160764T1 (hr) | 2016-08-12 |
Family
ID=39832293
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20160764TT HRP20160764T1 (hr) | 2007-05-08 | 2016-06-29 | Pseudovirusi papilomavirusa za otkrivanje i liječenje tumora |
Country Status (13)
Country | Link |
---|---|
US (4) | US8394411B2 (hr) |
EP (1) | EP2145189B1 (hr) |
AU (1) | AU2008251615B2 (hr) |
CA (1) | CA2686990C (hr) |
CY (1) | CY1117708T1 (hr) |
DK (1) | DK2145189T3 (hr) |
ES (1) | ES2575364T3 (hr) |
HR (1) | HRP20160764T1 (hr) |
HU (1) | HUE030437T2 (hr) |
PL (1) | PL2145189T3 (hr) |
PT (1) | PT2145189E (hr) |
SI (1) | SI2145189T1 (hr) |
WO (1) | WO2008140961A2 (hr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8394411B2 (en) * | 2007-05-08 | 2013-03-12 | The United States of America as represented by the Secretary, Dept. of Health and Human Services National Institutes of Health | Papillomavirus pseudoviruses for detection and therapy of tumors |
US20100222417A1 (en) * | 2008-11-26 | 2010-09-02 | Alnylam Pharmaceuticals | Compostions and methods for enhancing oligonucleotide delivery across and into epithelial tissues |
EP3427755B1 (en) | 2009-04-13 | 2020-10-21 | INSERM - Institut National de la Santé et de la Recherche Médicale | Hpv particles and uses thereof |
US20120225090A1 (en) * | 2009-08-03 | 2012-09-06 | The Johns Hopkins University | Methods for enhancing antigen-specific immune responses |
US20130115247A1 (en) * | 2011-11-05 | 2013-05-09 | Aura Biosciences, Inc. | Virion Derived Protein Nanoparticles For Delivering Radioisotopes For The Diagnosis And Treatment Of Malignant And Systemic Disease And The Monitoring Of Therapy |
US20130116408A1 (en) * | 2011-11-05 | 2013-05-09 | Aura Biosciences, Inc. | Virion Derived Protein Nanoparticles For Delivering Radioisotopes For The Diagnosis And Treatment Of Malignant And Systemic Disease And The Monitoring Of Therapy |
WO2013119877A1 (en) | 2012-02-07 | 2013-08-15 | Aura Biosciences, Inc. | Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells |
JP2016519570A (ja) | 2013-03-14 | 2016-07-07 | エペイウス バイオテクノロジーズ コーポレイション | 改善されたチミジンキナーゼ遺伝子 |
ES2917573T3 (es) * | 2013-09-18 | 2022-07-08 | Aura Biosciences Inc | Método de producción de moléculas fotosensibles |
WO2015187677A1 (en) * | 2014-06-02 | 2015-12-10 | Li-Cor, Inc. | Phthalocyanine probes and uses thereof |
CN104880555B (zh) * | 2015-06-19 | 2017-11-14 | 中国食品药品检定研究院 | 一种人***瘤病毒中和抗体的高通量检测方法 |
JP2018532801A (ja) | 2015-10-30 | 2018-11-08 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 標的化がん療法 |
MA43134A (fr) | 2015-10-30 | 2018-09-05 | Aleta Biotherapeutics Inc | Compositions et méthodes de transduction tumorale |
AU2016343809B2 (en) | 2015-10-30 | 2022-08-04 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
US10751398B2 (en) * | 2016-10-07 | 2020-08-25 | Loyola University Chicago | Inflammasome activators and methods of use to treat tumors |
KR20200027956A (ko) | 2017-06-23 | 2020-03-13 | 패쏘백스 엘엘씨 | 키메라 바이러스-유사 입자 및 면역 반응의 항원-특이적 재지향자로서의 이의 용도 |
WO2019090304A1 (en) | 2017-11-06 | 2019-05-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cancer treatment utilizing pre-existing microbial immunity |
JP2021508443A (ja) | 2017-12-15 | 2021-03-11 | アレタ・バイオセラピューティクス・インコーポレイテッドAleta Biotherapeutics Inc. | Cd19変異体 |
JP7287972B2 (ja) * | 2018-02-14 | 2023-06-06 | ユニバーシティ オブ ヒューストン システム | 循環腫瘍細胞のユニバーサル検出のためのプローブ |
CN113396155A (zh) | 2018-12-27 | 2021-09-14 | 维伊木恩股份有限公司 | 偶联病毒样颗粒及其作为抗肿瘤免疫重定向剂的用途 |
CN113881636B (zh) * | 2020-07-03 | 2024-05-03 | 贝勒知临(杭州)生物技术有限公司 | 一种游离细胞标记及分离探针及其相关产品和用途 |
WO2022087013A1 (en) | 2020-10-19 | 2022-04-28 | Verimmune Inc. | Virus-inspired compositions and methods of redirecting preexisting immune responses using the same for treatment of cancer |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1018875A (en) | 1911-02-13 | 1912-02-27 | Francois Edouard Cardon | Finger-ring construction. |
FR2749323B1 (fr) * | 1996-06-04 | 1998-07-10 | Pasteur Merieux Serums Vacc | Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique |
ES2572628T3 (es) * | 1997-09-05 | 2016-06-01 | Medimmune, Inc. | Método in vitro para desmontaje/remontaje de partículas análogas al virus del papiloma humano (VLP) |
CN1114690C (zh) | 2001-05-15 | 2003-07-16 | 乔良 | ***瘤假病毒及其制备方法 |
US8394411B2 (en) * | 2007-05-08 | 2013-03-12 | The United States of America as represented by the Secretary, Dept. of Health and Human Services National Institutes of Health | Papillomavirus pseudoviruses for detection and therapy of tumors |
-
2008
- 2008-05-01 US US12/598,684 patent/US8394411B2/en active Active
- 2008-05-01 SI SI200831643A patent/SI2145189T1/sl unknown
- 2008-05-01 PT PT08747407T patent/PT2145189E/pt unknown
- 2008-05-01 AU AU2008251615A patent/AU2008251615B2/en active Active
- 2008-05-01 PL PL08747407.8T patent/PL2145189T3/pl unknown
- 2008-05-01 HU HUE08747407A patent/HUE030437T2/en unknown
- 2008-05-01 WO PCT/US2008/062296 patent/WO2008140961A2/en active Application Filing
- 2008-05-01 DK DK08747407.8T patent/DK2145189T3/en active
- 2008-05-01 EP EP08747407.8A patent/EP2145189B1/en active Active
- 2008-05-01 ES ES08747407.8T patent/ES2575364T3/es active Active
- 2008-05-01 CA CA2686990A patent/CA2686990C/en active Active
-
2013
- 2013-02-08 US US13/763,365 patent/US8999290B2/en active Active
-
2014
- 2014-12-02 US US14/558,301 patent/US10188751B2/en active Active
-
2016
- 2016-06-29 HR HRP20160764TT patent/HRP20160764T1/hr unknown
- 2016-07-01 CY CY20161100607T patent/CY1117708T1/el unknown
-
2018
- 2018-12-28 US US16/235,152 patent/US10814014B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2008251615B2 (en) | 2014-09-18 |
US8999290B2 (en) | 2015-04-07 |
SI2145189T1 (sl) | 2016-08-31 |
HUE030437T2 (en) | 2017-05-29 |
CA2686990A1 (en) | 2008-11-20 |
PT2145189E (pt) | 2016-06-16 |
EP2145189B1 (en) | 2016-04-06 |
CY1117708T1 (el) | 2017-05-17 |
US20100135902A1 (en) | 2010-06-03 |
US20130230456A1 (en) | 2013-09-05 |
ES2575364T3 (es) | 2016-06-28 |
WO2008140961A2 (en) | 2008-11-20 |
DK2145189T3 (en) | 2016-06-06 |
US10814014B2 (en) | 2020-10-27 |
EP2145189A2 (en) | 2010-01-20 |
PL2145189T3 (pl) | 2016-09-30 |
WO2008140961A3 (en) | 2009-06-18 |
US8394411B2 (en) | 2013-03-12 |
US10188751B2 (en) | 2019-01-29 |
US20190290782A1 (en) | 2019-09-26 |
CA2686990C (en) | 2018-04-24 |
AU2008251615A1 (en) | 2008-11-20 |
US20150157738A1 (en) | 2015-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20160764T1 (hr) | Pseudovirusi papilomavirusa za otkrivanje i liječenje tumora | |
IL201383A0 (en) | Melatonin tablet and methods of preparation and use | |
ZA201101132B (en) | Signatures and pcdeterminants associated with prostate cancer and methods of use thereof | |
EP2277049A4 (en) | AUTOANTIBODIES IN THE DETECTION AND TREATMENT OF CANCER | |
HK1156631A1 (en) | Novel compounds and methods for therapy | |
EP2370593A4 (en) | METHOD FOR THE TREATMENT OF INFECTIONS AND TUMORS | |
AP2860A (en) | Carbazole compounds and therapeutic uses of the compounds | |
EP2652506A4 (en) | USE OF ANTIBODIES AGAINST CXCL16 AND CXCR6 FOR TREATMENT OR FOR THE DETECTION OF CANCER | |
EP2250287A4 (en) | PROOF AND FORECAST OF LUNG CANCER | |
EP2652508A4 (en) | USE OF ANTI-CXCL13 ANTI-CXCR5 ANTIBODIES FOR THE TREATMENT OR DETECTION OF CANCER | |
EP2408465A4 (en) | METHOD AND COMPOSITIONS FOR DETECTING CANCER | |
EP2526221A4 (en) | SET OF PROBES FOR THE DETECTION AND TYPING OF 46 HUMAN PAPILLOMAVIRUS OF MUCOUS TYPES | |
EP2295598A4 (en) | METHOD AND KIT FOR DETECTING CANCER, AND THERAPEUTIC AGENT FOR CANCER | |
GB0820309D0 (en) | Detection of cancer | |
IL212800A0 (en) | N-cadherin: target for cancer diagnosis and therapy | |
HK1151828A1 (en) | Primer set and probe for detection of human papillomavirus | |
EP2635121A4 (en) | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | |
EP2285983A4 (en) | USE OF RUNX3 AND MIR-532-5P AS CANCER MARKERS AND THERAPY TARGETS | |
EP2337868A4 (en) | DETECTION OF TUMORS OF GRANULOSA | |
EP2361317A4 (en) | USE OF EIF3M FOR THE DIAGNOSIS AND TREATMENT OF CANCER | |
SG10201701286YA (en) | Cancer detection methods and techniques | |
GB0702557D0 (en) | Detection of human papillomavirus | |
EP2419111A4 (en) | CANCER THERAPY SENSITIZING AGENTS, METHODS OF USE, AND METHODS OF IDENTIFYING THESE AGENTS | |
HK1209754A1 (en) | Compounds and methods for the treatment of cancer | |
GB0700281D0 (en) | Methods and Means for the Treatment of Cancer |